Evidence map›Paper›PMID 39980541›Full record

ArticleFrontiers in oncology2025

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study.

Toshiaki Tsurui, Kazuyuki Hamada, Emiko Mura, Risako Suzuki, Nana Iriguchi, Tomoyuki Ishiguro, Yuya Hirasawa, Ryotaro Ohkuma, Masahiro Shimokawa, Hirotsugu Ariizumi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Toshiaki TsuruiDivision of Medical Pharmacology, Showa University Graduate School of Medicine, Tokyo, Japan.
Kazuyuki HamadaDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Emiko MuraDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Risako SuzukiDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Nana IriguchiDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Tomoyuki IshiguroDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Yuya HirasawaDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Ryotaro OhkumaDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Masahiro ShimokawaDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Hirotsugu AriizumiDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Yutaro KubotaDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Atsushi HoriikeDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Satoshi WadaDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.
Kiyoshi YoshimuraDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
Mayumi TsujiPharmacological Research Center, Showa University, Tokyo, Japan.
Yuji KiuchiDivision of Medical Pharmacology, Showa University Graduate School of Medicine, Tokyo, Japan.
Takuya TsunodaDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In patients with cancer, sarcopenia is an indicator of poor prognosis and is associated with an increased risk of chemotherapy-related adverse events. Skeletal muscle interacts with the immune system, and sarcopenia is associated with immune senescence. However, the association between sarcopenia and the response to immune checkpoint inhibitor (ICI) therapy remains unclear. Methods: This retrospective study included patients with advanced or recurrent non-small cell lung cancer treated with nivolumab or pembrolizumab monotherapy. The association between the psoas muscle index (PMI) and both clinical response and immune-related adverse events (irAEs) was assessed using logistic regression. The PMI was calculated as the cross-sectional area of the psoas muscle divided by the square of the height based on computed tomography scans performed before the initial administration of ICI therapy. Results: A total of 67 patients were included in the analysis. Logistic regression analysis showed that PMI was associated with the overall response (odds ratio [OR]: 1.52; 95% confidence interval [CI]: 1.04-2.22; Conclusion: These findings suggest that PMI is both an indicator of prognosis and a surrogate marker of immunocompetence in predicting the clinical response to ICI therapy.

Indexed as

immune checkpoint inhibitorsimmunotherapylung neoplasmsretrospective studysarcopenia

Identifiers

PMID39980541
PMCPMC11839410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.